Cannabis for Orthopaedic Pain: Systematic Review Evidence (2025)
A 2025 systematic review evaluated cannabinoids orthopaedic pain systematic review evidence across 12 RCTs. The findings show limited but promising analgesic effects compared to placebo. Adverse effects were generally mild to moderate, highlighting the…
Smart Cannabis Digital Therapeutics: Commentary Analysis
Smart cannabis digital therapeutics propose pairing medical cannabis with FDA-regulated smartphone-based tools for personalized dosing. This conceptual model aims to address current gaps in cannabis care but lacks trial data. The commentary highlights…
Cannabis Use and Excessive Social Media in College Students
A 2025 survey of U.S. college students reveals cannabis use college students 2025 is linked to higher odds of excessive social media use. The study highlights a gradient by cannabis risk level but cannot confirm causation. Understanding cannabis use…
Cannabis Adverse Reactions in Canada: 6 Years of Safety Data
Canada's cannabis adverse reaction reports reveal six years of safety data highlighting common symptoms and product types involved. This analysis focuses on spontaneous reports collected by Health Canada, emphasizing the limitations in estimating true…
Cannabis Drug Interactions in Chronic Disease: Thai Study Findings
A new study highlights cannabis drug interactions chronic disease in Thailand, revealing many patients unaware of risks. Most chronic disease patients use cannabis but lack knowledge of its effects on medications. This awareness gap calls for improved…
FDA Botanical Drug Pathway for Cannabis: Why Zero Approvals Exist
The FDA botanical drug pathway cannabis presents unique challenges that have prevented approvals of cannabis-derived products. Scientific, regulatory, and logistical barriers contribute to this gap. Understanding these obstacles is essential for…
Canada 2015 Cannabis Survey: Medical vs Recreational User Profiles
The cannabis epidemiology medical cannabis population survey from 2015 reveals key differences between medical and recreational users in Canada before legalization. Medical users tended to be older, in poorer health, and used cannabis more frequently.…
Selonabant Blocks THC High in Phase II Trial | Evidence Watch
The selonabant CB1 antagonist sharply reduced subjective THC intoxication in a sponsored Phase II trial of healthy volunteers. Because selonabant was given alongside THC rather than after intoxication set in, the study cannot confirm whether it would…
Multi-Modal Cannabis Use Among Young Adults: BRFSS 2022-2023
Multi-modal cannabis use young adults is increasingly common, with over half using multiple consumption methods. The 2022-2023 BRFSS survey reveals key patterns and risk factors. Understanding these trends is vital for clinical screening and public…
Medical Cannabis and Healthcare Professionals: Beyond Knowledge Gaps
Medical cannabis implementation faces challenges beyond knowledge gaps among healthcare professionals. This review highlights the importance of social norms, professional identity, and environmental barriers. Addressing these factors is crucial for…
